This is an aggregated industry headline. Read the full story at FiercePharma →
Editor's Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patients, Angus Liu argues in an editorial.
By FiercePharma
· Aug 3, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, co…
The WeekBriefing
Three Asia-linked developments stood out: a CEO exit at Legend, a quickly deleted Merck trial posting, and an …
The WeekPharmaVoice ↗
How Evonik is shaping more sustainable oral drug delivery through data and excipient innovation.…